Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Xuanzhu Biopharmaceutical Co., Ltd.
軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

VOLUNTARY ANNOUNCEMENT

LICENSING AND SUPPLY AGREEMENT WITH BOSTON ONCOLOGY FOR BIREOCICLIB AND DIROZALKIB

The board of directors (the "**Board**") of Xuanzhu Biopharmaceutical Co., Ltd. (the "**Company**" or "**Xuanzhu Biopharm**", together with its subsidiaries, the "**Group**") is pleased to announce that, on April 9, 2026, the Group (the "**Licensor**") entered into a licensing and supply agreement (the "**Agreement**") with Boston Oncology CGT Holding Co. Limited (the "**Licensee**") in respect of Bireociclib (trade name: Xuan Yue Ning) and Dirozalkib (trade name: Xuan Fei Ning). Bireociclib is a CDK2/4/6 inhibitor independently developed by the Group for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ("**HR+/HER2-**") advanced breast cancer; Dirozalkib is a next-generation anaplastic lymphoma kinase ("**ALK**") inhibitor independently developed by the Group for the treatment of ALK-positive advanced non-small cell lung cancer.

Under the licensing and supply agreement, the Licensor will grant the Licensee an exclusive license to develop, register and commercialize Bireociclib and Dirozalkib within the licensed territory (21 countries and regions in the Middle East and North Africa (MENA) region). The Licensor will receive an upfront payment and potential regulatory and commercial milestone payments which may cumulatively exceed USD100 million, as well as royalties at a fixed percentage of total sales within the licensed territory. The Licensor will supply products to the Licensee at product supply prices agreed upon by both parties, so as to meet the commercial development activities for both drugs within the licensed territory.

The execution of the Agreement is an important strategic initiative for the Group in its global market expansion. Leveraging the Licensee's established advantages in pharmaceutical registration, commercial promotion and distribution systems within the MENA region, the Group can rapidly advance the market entry and commercialization of Bireociclib and Dirozalkib in the licensed territory, thereby further enhancing the global market coverage and brand influence of the Group's innovative drugs. At the same time, the fulfillment of the Agreement will bring sustained milestone and royalty income to the Group, optimize its revenue structure, and is in the overall interests of the Group and all of its shareholders.

ABOUT BIREOCICLIB

Bireociclib Tablets (trade name: Xuan Yue Ning), as the first CDK2/4/6 inhibitor approved in China, possesses a unique multi-target synergistic mechanism of action, offering advantages including potent inhibition of tumor cell proliferation and significant reduction of the hematological toxicity commonly associated with traditional CDK4/6 inhibitors. In May 2025, Bireociclib Tablets were approved by the National Medical Products Administration (NMPA) for use in combination with fulvestrant for the treatment of adult patients with HR+/HER2- locally advanced or metastatic breast cancer who have experienced disease progression following prior endocrine therapy; and as monotherapy for the treatment of adult patients with HR+/HER2- advanced or metastatic breast cancer who have experienced disease progression following two or more prior endocrine therapies and one chemotherapy regimen during the metastatic stage, making it the first and only CDK2/4/6 inhibitor approved with a monotherapy indication in China. In March 2026, Bireociclib Tablets received approval for an additional indication, for use in combination with aromatase inhibitors (AIs) for the initial endocrine treatment of patients with HR+/HER2- locally advanced or metastatic breast cancer. In December 2025, both indications for Bireociclib Tablets, in combination with fulvestrant and as monotherapy, were included in the National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List (2025), effective from January 1, 2026.

ABOUT DIROZALKIB

Dirozalkib Tablets (trade name: Xuan Fei Ning) are a next-generation oral ALK inhibitor independently developed by the Group, specifically designed for the treatment of ALK-rearranged advanced non-small cell lung cancer (NSCLC). Dirozalkib features a novel molecular structure with stronger affinity for the ATP-binding site within the ALK kinase domain, demonstrating potent inhibitory activity against common resistance mutations associated with first-generation and most second-generation ALK inhibitors, including G1202R and I1171N, and is capable of achieving significant intracranial anti-tumor efficacy through efficient penetration of the blood-brain barrier. In August 2025, Dirozalkib was approved by the NMPA for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not been previously treated with an anaplastic lymphoma kinase (ALK) inhibitor.

ABOUT THE LICENSEE

Boston Oncology CGT Holding Co. Limited is headquartered in Cambridge, Massachusetts, United States, with a regional operations center established in Riyadh, Saudi Arabia. The company focuses on the localized development, production and manufacturing of oncology drugs and biosimilars. Through pharmaceutical licensing, technology transfer and regionalized production models, it introduces international quality and manufacturing standards to the Middle East market, continuously advancing the local supply of drugs in key therapeutic areas and supporting the coordinated development of the regional pharmaceutical industry. As far as the directors are aware after making all reasonable enquiries, Boston Oncology CGT Holding Co. Limited and its ultimate beneficial owners are independent third parties independent of the Company and its connected persons (as defined in the Listing Rules).

IMPLICATIONS UNDER THE LISTING RULES

As the transactions contemplated under the licensing agreement are revenue-generating transactions in the ordinary and usual course of business of the Group, the entering into of the licensing agreement does not constitute a notifiable transaction under Chapter 14 of the Listing Rules.

RISK FACTORS

The progress and outcome of the regulatory filing and approval for marketing authorization by local regulatory authorities for Bireociclib and Dirozalkib within the licensed territory under the Agreement are subject to multiple factors including regional regulatory policies and approval requirements, and there remains some uncertainty as to whether the marketing authorization can be successfully obtained within the licensed scope. In addition, the payment of various amounts under the Agreement, including the upfront payment, regulatory and commercial milestone payments, is subject to the satisfaction of the payment conditions stipulated in the Agreement. The subsequent actual payment amounts and payment milestones are influenced by factors such as the progress of product marketing and the effectiveness of commercial promotion, and the ultimately realizable payment amounts remain uncertain. Investors are advised to exercise caution in making investment decisions and to be mindful of investment risks. The Company will strictly comply with the requirements of applicable laws, regulations and the Listing Rules, and will timely fulfill its information disclosure obligations in respect of any subsequent developments of this project.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun
Chairperson of the Board and executive Director

Hong Kong, 9 April 2026

As of the date of this announcement, the Board of the Company comprises (i) Ms. Xu Yanjun, Dr. Li Jia Kui and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; and (iii) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.